neurodegenerative diseases

Graphic image of a red thumbs down against a blue background
Biotech

FDA rejects Biohaven approval request, triggering cost cutting

Biohaven responded to the rejection of its neurological disorder therapy by reprioritizing its pipeline to shrink its annual R&D spend by 60%.
Nick Paul Taylor Nov 5, 2025 4:02am
Space shuttle takes off on background of blue sky

Roche signs $2B pact to pilot Manifold's shuttles to the brain

Nov 3, 2025 8:45am
brain

Alector halves staff after GSK-partnered antibody fails in ph. 3

Oct 22, 2025 11:23am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

2 European biotechs link to tackle neurodegenerative diseases

Oct 20, 2025 8:20am
business targets illustration

uniQure plans FDA push after Huntington's gene therapy trial win

Sep 24, 2025 9:20am
IPO initial public offering Wall Street

Big Pharma-backed MapLight plots IPO

Sep 22, 2025 1:57pm